Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025
Eledon Pharmaceuticals (NASDAQ:ELDN) has announced a conference call and webcast scheduled for August 6, 2025, at 4:30 p.m. ET to discuss updated clinical data from their ongoing Phase 1b study of tegoprubart in kidney transplantation.
The presentation will feature data from approximately 30 kidney transplant recipients and will be presented at the World Transplant Congress (WTC) in San Francisco. The study focuses on tegoprubart's potential in preventing rejection in kidney transplant patients.
Eledon Pharmaceuticals (NASDAQ:ELDN) ha annunciato una conference call e una webcast programmate per il 6 agosto 2025 alle 16:30 ET per discutere i dati clinici aggiornati del loro studio di Fase 1b in corso su tegoprubart nel trapianto renale.
La presentazione includerà dati provenienti da circa 30 riceventi di trapianto renale e sarà presentata al World Transplant Congress (WTC) a San Francisco. Lo studio si concentra sul potenziale di tegoprubart nella prevenzione del rigetto nei pazienti con trapianto renale.
Eledon Pharmaceuticals (NASDAQ:ELDN) ha anunciado una llamada de conferencia y una transmisión en línea programadas para el 6 de agosto de 2025 a las 4:30 p.m. ET para discutir datos clínicos actualizados de su estudio en curso de Fase 1b sobre tegoprubart en trasplante renal.
La presentación incluirá datos de aproximadamente 30 receptores de trasplante renal y se presentará en el World Transplant Congress (WTC) en San Francisco. El estudio se centra en el potencial de tegoprubart para prevenir el rechazo en pacientes con trasplante renal.
Eledon Pharmaceuticals (NASDAQ:ELDN)는 2025년 8월 6일 오후 4시 30분 ET에 진행 중인 신장 이식 환자를 대상으로 한 1b상 임상시험 tegoprubart의 최신 임상 데이터를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 발표했습니다.
발표에는 약 30명의 신장 이식 수혜자 데이터가 포함되며, 샌프란시스코에서 열리는 세계 이식 학회(World Transplant Congress, WTC)에서 발표될 예정입니다. 이 연구는 신장 이식 환자에서 거부 반응 예방을 위한 tegoprubart의 가능성에 초점을 맞추고 있습니다.
Eledon Pharmaceuticals (NASDAQ:ELDN) a annoncé une conférence téléphonique et une webdiffusion prévues pour le 6 août 2025 à 16h30 ET afin de discuter des données cliniques mises à jour de leur étude de phase 1b en cours sur le tegoprubart dans la transplantation rénale.
La présentation comprendra des données provenant d'environ 30 receveurs de greffe rénale et sera présentée au World Transplant Congress (WTC) à San Francisco. L'étude porte sur le potentiel du tegoprubart pour prévenir le rejet chez les patients transplantés rénaux.
Eledon Pharmaceuticals (NASDAQ:ELDN) hat eine Telefonkonferenz und ein Webcast für den 6. August 2025 um 16:30 Uhr ET angekündigt, um aktualisierte klinische Daten ihrer laufenden Phase-1b-Studie zu Tegoprubart bei Nierentransplantationen zu besprechen.
Die Präsentation wird Daten von etwa 30 Nierentransplantatempfängern enthalten und auf dem World Transplant Congress (WTC) in San Francisco vorgestellt. Die Studie konzentriert sich auf das Potenzial von Tegoprubart zur Verhinderung von Abstoßungen bei Nierentransplantationspatienten.
- None.
- None.
IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the company will host a conference call and webcast on Wednesday, August 6, 2025 at 4:30 p.m. ET to discuss updated clinical data from its ongoing open-label Phase 1b study evaluating tegoprubart for the prevention of rejection in subjects undergoing kidney transplantation. These data, from approximately 30 kidney transplant recipients, are being presented at the World Transplant Congress (WTC) in San Francisco, CA on August 6, 2025.
To join the conference call, please dial 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. The conference ID is 34575. Registration for the live webcast can be found here and available on the “Events” section of Eledon’s website at www.eledon.com. The webcast will be archived on the website following the completion of the call.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
When is Eledon Pharmaceuticals (ELDN) hosting its conference call to discuss tegoprubart kidney transplant data?
How many patients are included in Eledon's (ELDN) tegoprubart kidney transplant study?
What is the purpose of Eledon's (ELDN) tegoprubart Phase 1b study?
How can investors access Eledon's (ELDN) conference call on August 6?
